Oxford University
To add a bio or update investment portfolio, please click update information.
Investment Portfolio
RQ Bio raises a £86m Series A led by Frazier Life Sciences to develop long-acting antibody protection against seasonal influenza
RQ Bio is a UK-based biotechnology company developing long-acting monoclonal antibodies against seasonal influenza. Its lead programme, RQB01, is designed to deliver potent, broad-strain protection against influenza through a dual mechanism of action, targeting patients whose immune systems cannot rely on vaccination alone.
Scripta Therapeutics raises £9m seed led by Oxford Science Enterprises and Apollo Health Ventures to upend conventional drug discovery
Scripta Therapeutics applies AI and experimental biology to map disease-driving transcription networks, aiming to identify new drug targets for neurodegenerative and complex conditions.
Wild Bio secures £45m Series A led by the Ellison Institute of Technology to boost crop resilience by learning from wild species
Wild Bio applies AI and precision breeding to crop genetics, using insights from wild plant species to develop climate-resilient, higher-yield crop varieties for commercial agriculture.
Ultromics raises £40m Series C led by L&G, Allegis Capital and Lightrock to expand AI heart failure diagnostics in the US
Ultromics develops AI software that analyses echocardiograms to help clinicians detect hard-to-diagnose heart failure conditions earlier, without requiring new hardware or changes to existing clinical workflows.
- 4(12 months)
- ox.ac.uk
- Update Information
More venture news
- 14 Jul 2026
ValarianValarian raises a £37m Series A round led by NEA to provide sovereign control over AI workloads
Series ADefence - 14 Jul 2026
GridcogGridcog secures £7m in a Series A round led by ABB for its energy flexibility modelling platform
Series AEnergy - 14 Jul 2026
VelocityVelocity announces £28m Series A led by Dragonfly and FirstMark for stablecoin treasury and settlement infrastructure
Series AFintech
